ライフサイエンスコーパス: anginal

1 Expected survival rates are good, as are the anginal and functional classifications, but there is a h

2 r =1-mm ST-segment depression, average daily anginal attack count and nitroglycerin usage.

3 e patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dos

4 among several compounds suggested to trigger anginal chest pain; however, the pH reached when a coron

5 The statistically significant reduction in anginal class and strong positive trends for remaining e

6 At six months, the anginal class improved by two or more classes in 49% of

7 th complete 12-month follow-up (n =27), mean anginal class improved from 3.5+/-0.5 pre-TMR to 2.8+/-0

8 Anginal complaints improved </=12 months after cell inje

9 d with improvements in myocardial perfusion, anginal complaints, and quality of life score </=12 mont

10 Ranolazine, an anti-anginal compound, has been shown to significantly improv

11 onship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration.

12 hat is unknown, however, is whether any anti-anginal drugs (beta-blockers, long-acting nitrates, calc

13 e anti-ischemic therapy for their qualifying anginal episode and less likely to undergo invasive proc

14 Our analysis shows an improvement in anginal episodes (MD, -7.81; 95% confidence interval [CI

15 disease, were more likely than men to report anginal episodes and had more recorded ischemic periods

16 Anginal episodes and nitroglycerin use were recorded wit

17 Many patients with chronic angina experience anginal episodes despite revascularization and antiangin

18 e in increasing exercise testing or reducing anginal episodes or use of glyceryl trinitrate.

19 ary outcome was the average weekly number of anginal episodes over the last 6 weeks of the study.

20 The outcomes pooled were indices of angina (anginal episodes, Canadian Cardiovascular Society angina

21 or = 50%), severe anginal symptoms (> or = 2 anginal events in preceding 24 h), use of aspirin in the

22 lectrocardiogram at presentation, at least 2 anginal events in prior 24 hours, use of aspirin in prio

23 everal dimensions of HRQOL including reduced anginal frequency and bodily pain as well as improved di

24 diovascular outcome, notably higher rates of anginal hospitalization, repeat catheterization, and gre

25 Anginal improvement occurred with a reduction in Canadia

26 th angina-limited exercise discontinued anti-anginal medications and were randomized into a double-bl

27 cular clinical relevance because chest pain, anginal or otherwise, has been shown to be a frequent bu

28 case history of an individual with possible anginal pain and asked how respondents would react to ex

29 xcept C7 and C8 segments, contributes to the anginal pain experienced in the chest and arm.

30 This innervation contributes to the anginal pain experienced in the neck and jaw.

31 neous thermal pain thresholds are related to anginal pain perception.

32 ld consist of a combined antithrombotic/anti-anginal regimen.

33 The impact of these findings on anginal relief and long-term outcome are not known.

34 ll p < or = 0.03) and a trend towards better anginal stability (p = 0.056).

35 The SAQ scores for exertional capacity, anginal stability and frequency, treatment satisfaction,

36 ciation between repeat revascularization and anginal status, according to the type of initial revascu

37 The patient-oriented composite endpoint, anginal status, and exercise testing, were not statistic

38 monly used despite the marked improvement in anginal status.

39 AD), known CAD (stenosis > or = 50%), severe anginal symptoms (> or = 2 anginal events in preceding 2

40 ss surgery persisted among those with severe anginal symptoms (31 percent of blacks underwent surgery

41 clinical presentation with exercise-related anginal symptoms (chest pain or dyspnea) with or without

42 sts because of their efficacy in controlling anginal symptoms (Dihydropyridine calcium channel blocke

43 policy of PTCA was associated with improved anginal symptoms and exercise times.

44 s may explain how aortic stenosis can induce anginal symptoms and their prompt relief after PAVR.

45 evascularization especially if minimal or no anginal symptoms are present.

46 4, P<10-7) identified inducible ischemia and anginal symptoms as the most powerful predictors (83%, 6

47 Asians and Europeans interpret and act upon anginal symptoms differently.

48 ith improvements in myocardial perfusion and anginal symptoms in patients with refractory angina pect

49 ter likelihood of seeking immediate care for anginal symptoms than Europeans; this finding indicates

50 n, mean age 66 +/- 10 years) with exertional anginal symptoms undergoing diagnostic angiography.

51 By contrast, when anginal symptoms were relieved in five subjects by cessa

52 He developed typical anginal symptoms within 2 wk of discharge; however, coro

53 ention (PCI) is usually performed to relieve anginal symptoms, but data are emerging to suggest that

54 icrovascular coronary spasm in patients with anginal symptoms, despite angiographically normal corona

55 eral trials have demonstrated a reduction in anginal symptoms, increases in exercise tolerance, and o

56 or IS could be attributed to improvements in anginal symptoms.

57 exercise thallium studies for evaluation of anginal symptoms.

58 tective effects of preinfarction angina, the anginal "warm-up phenomenon," and studies performed on h